Format

Send to

Choose Destination
J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30502-7. doi: 10.1016/j.jtho.2019.06.020. [Epub ahead of print]

Pathologic considerations and standardization in mesothelioma clinical trials.

Author information

1
Department of Pathology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
2
Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, HI.
3
MESOPATH, MESONAT, MESOBANK, Department of BioPathology, Centre Leon Berard, Lyon, France.
4
Department of Pathology, New York University Langone Health, New York, New York.
5
Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom.
6
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
7
Division of Medical Oncology, Mayo Clinic, Rochester, MN.
8
Mesothelioma Research Programme, Leicester Cancer Research Centre, Leicester.
9
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
10
Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
11
Mesothelioma Applied Research Foundation, Alexandria, Virginia.
12
Mount Sinai Health System, Center for Thoracic Oncology/Tisch Cancer Center. NYC, NY.
13
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
14
Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
15
National Centre for Asbestos Related Disease, University of Western Australia, Nedlands, Western Australia, Australia.
16
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
17
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
18
Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
19
Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
20
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
21
Division of Medical Oncology, Mayo Clinic, Rochester, MN. Electronic address: Mansfield.aaron@mayo.edu.

Abstract

The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking and tissue correlative studies.

KEYWORDS:

Mesothelioma; clinical trials; correlatives; pathologic classification; pathology

PMID:
31260832
DOI:
10.1016/j.jtho.2019.06.020

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center